WO2026125941 - LYN KINASE ACTIVATORS FOR USE IN TREATING FIBROSIS OR DISEASES ASSOCIATED WITH FIBROSIS
National phase entry is expected:
Publication Number
WO/2026/125941
Publication Date
18.06.2026
International Application No.
PCT/IB2025/000644
International Filing Date
12.12.2025
Title **
[English]
LYN KINASE ACTIVATORS FOR USE IN TREATING FIBROSIS OR DISEASES ASSOCIATED WITH FIBROSIS
[French]
ACTIVATEURS DE KINASE LYN À UTILISER POUR TRAITER LA FIBROSE OU DES MALADIES ASSOCIÉES À LA FIBROSE
Applicants **
BIODEXA LTD.
Inventors
PALMER, Dan
Priority Data
63/733,475
13.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2440 | |
| EPO | Filing, Examination, Granting | 12170 | |
| Japan | Filing, Examination, Granting | 2356 | |
| South Korea | Filing, Examination, Granting | 2421 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
24,327
Contact Us
Abstract[English]
Methods for treating a monocyte-driven disease (such as fibrosis) with a Lyn kinase activator are provided. Also provided are methods of slowing fibrosis progression in a subject by administering to the subject a therapeutically effective amount of a Lyn kinase activator.[French]
L'invention concerne des méthodes de traitement d'une maladie induite par des monocytes (telle que la fibrose) avec un activateur de kinase Lyn. L'invention concerne également des méthodes destinées à ralentir la progression de la fibrose chez un sujet par administration au sujet d'une quantité thérapeutiquement efficace d'un activateur de kinase Lyn.